Skip to the list
English

Clinical-stage biotech

The 200 companies in this industry listed on the NYSE and Nasdaq are worth $120 bn combined; the largest are Summit Therapeutics Inc. (SMMT), Spyre Therapeutics, Inc. (SYRE) and Kodiak Sciences Inc. (KOD). For each one: what it does, revenue, margin, free cash flow over the last five years and a score from 0 to 10.

Data as of October 2026

Evenly matched
200 companies value 120 bn revenue 0.8 bn margin -891.3% free cash flow -15 bn avg. score 0.3
SMMT holds 10.3% of the group's value, 1.7x the runner-up
Rank Ticker Company Share Value Revenue Margin FCF 5 years FCF/px Yield What it does · why it is here
1 SMMT Summit Therapeutics Inc.
United States · score 0.0
 10% 12 bn — — -0.5 bn -3.7% — Biopharma discovering and developing oncology therapies · Florida
2 SYRE Spyre Therapeutics, Inc.
United States · score 0.1
 6% 7.5 bn 0.0 bn — -0.2 bn -2.8% — Clinical-stage biotech of antibodies for inflammatory bowel disease · Massachusetts
3 KOD Kodiak Sciences Inc.
United States · score 0.0
 5% 5.7 bn — — -0.2 bn -2.8% — Medicines for retinal diseases, with the ABC platform · California
4 IMVT Immunovant, Inc.
United States · score 0.0
 5% 5.7 bn — — -0.4 bn -7.3% — Clinical-stage immunology for autoimmune diseases · North Carolina
5 CGON CG Oncology, Inc.
United States · score 0.0
 4% 5.3 bn 0.0 bn -36x -0.2 bn -3.4% — Clinical-stage biopharma of oncolytic immunotherapy · Texas — revenue of $6m
6 SRRK Scholar Rock Holding Corp
United States · score 0.0
 4% 4.9 bn 0.0 bn — -0.3 bn -6.1% — Treatment for spinal muscular atrophy · Massachusetts
7 ORKA Oruka Therapeutics, Inc.
United States · score 0.2
 4% 4.9 bn — — -0.1 bn -2.1% — Clinical-stage biopharma of antibodies for psoriasis · California
8 CRSP CRISPR Therapeutics AG
Switzerland · score 0.0
 4% 4.8 bn 0.0 bn -34x -0.4 bn -7.7% — Biopharma of CRISPR/Cas9-based therapies · Switzerland — revenue of $13m
9 DNTH Dianthus Therapeutics, Inc. /DE/
United States · score 0.0
 4% 4.2 bn 0.0 bn -94x -0.2 bn -3.7% — Clinical-stage biotech in therapies for severe autoimmune diseases · New York — revenue of $2m
10 DNLI Denali Therapeutics Inc.
United States · score 0.0
 2% 2.9 bn 0.0 bn -142x -0.4 bn -15.2% — Therapies that cross the blood-brain barrier · California — revenue of $4m
11 DYN Dyne Therapeutics, Inc.
United States · score 0.0
 2% 2.8 bn — — -0.5 bn -16.9% — Clinical-stage biotech in genetic neuromuscular diseases · Massachusetts
12 CELC Celcuity Inc.
United States · score 0.0
 2% 2.8 bn — — -0.2 bn -6.9% — Clinical-stage biotech in solid tumor therapies · Minnesota
13 CLDX Celldex Therapeutics, Inc.
United States · score 0.0
 2% 2.3 bn 0.0 bn -1902x -0.2 bn -10.4% — Biopharma of antibodies for inflammatory and allergic diseases · New Jersey
14 VERA Vera Therapeutics, Inc.
United States · score 0.0
 2% 2.1 bn — — -0.3 bn -16.3% — Treatments for serious immune diseases · California
15 ZBIO Zenas BioPharma, Inc.
United States · score 0.0
 1% 1.7 bn 0.0 bn -484x -0.2 bn -13.0% — Clinical-stage biopharma in immune therapies · Massachusetts — revenue of $1m
16 GENB Generate Biomedicines, Inc.
United States · score 0.0
 1% 1.6 bn 0.0 bn -897.7% -0.2 bn — -15.2% — Protein and drug discovery with generative biology · Massachusetts — revenue of $26m
17 STOK Stoke Therapeutics, Inc.
United States · score 0.0
 1% 1.6 bn 0.0 bn -753.6% -0.2 bn -11.3% — Clinical-stage biotech of RNA medicines · Massachusetts — revenue of $28m
18 QURE uniQure N.V.
Netherlands · score 0.0
 1% 1.5 bn 0.0 bn -16x -0.2 bn -10.5% — Gene therapies for Huntington's, epilepsy, Fabry and ALS · Netherlands — revenue of $16m
19 ABSI Absci Corp
United States · score 0.0
 1% 1.5 bn 0.0 bn -78x -0.1 bn -7.4% — Clinical-stage biopharma of AI-designed antibodies · Washington — revenue of $2m
20 COAG Hemab Therapeutics Holdings, Inc.
United States · score 5.0
 1% 1.5 bn — — — — — — Therapies for rare bleeding disorders · Massachusetts
21 TSHA Taysha Gene Therapies, Inc.
United States · score 0.0
 1% 1.3 bn 0.0 bn -27x -0.1 bn -10.3% — Clinical-stage biotech of AAV gene therapy for CNS diseases · Texas — revenue of $5m
22 INBX Inhibrx Biosciences, Inc.
United States · score 0.0
 1% 1.3 bn 0.0 bn — -0.1 bn -10.0% — Clinical-stage biopharma of protein-engineered biologics · California
23 TRAX First Tracks Biotherapeutics, Inc.
United States · score 5.0
 1% 1.3 bn — — — — — — Therapies for celiac and autoimmune diseases · California
24 OMER OMEROS CORP
United States · score 0.7
 1% 1.2 bn 0.0 bn 324.9% -0.1 bn -5.8% — Commercial biotech in complement-mediated disease therapies · Washington — revenue of $38m
25 SLN Silence Therapeutics plc
United Kingdom · score 0.0
 1% 1.2 bn 0.0 bn -97x -0.0 bn -3.5% — siRNA molecule biotech · United Kingdom
26 DMRA Damora Therapeutics, Inc.
United States · score 0.0
 1% 1.2 bn — — -0.0 bn -3.7% — Biopharma of therapies for blood disorders · Massachusetts
27 BCAX Bicara Therapeutics Inc.
United States · score 0.0
 1% 1.2 bn — — -0.1 bn -11.7% — Clinical-stage biopharma in bifunctional therapies for solid tumors · Massachusetts
28 VOR Vor Biopharma Inc.
United States · score 0.5
 1% 1.1 bn — — -0.1 bn -13.2% — Clinical-stage biopharma of therapy for autoimmune diseases · Massachusetts
29 IMTX Immatics N.V.
Germany · score 0.0
 1% 1.1 bn — — -0.2 bn -22.1% — T-cell immunotherapies for cancer, from Germany · Germany
30 JANX Janux Therapeutics, Inc.
United States · score 0.0
 1% 1.0 bn 0.0 bn -427.5% -0.0 bn -4.1% — Clinical-stage T cell engagers for oncology · California — revenue of $24m
31 REPL Replimune Group, Inc.
United States · score 0.0
 1% 1.0 bn — — -0.3 bn -26.9% — Clinical-stage biotech of oncolytic immunotherapy · Massachusetts
32 SVRA Savara Inc
United States · score 0.0
 1% 1.0 bn — — -0.1 bn -11.6% — Clinical-stage biopharma in rare respiratory diseases · Texas
33 CGEM Cullinan Therapeutics, Inc.
United States · score 0.0
 1% 0.9 bn — — -0.2 bn -17.7% — Biopharma of therapies for autoimmune diseases and cancer · Massachusetts
34 JBIO Jade Biosciences, Inc.
United States · score 0.0
 1% 0.9 bn — — -0.1 bn -14.1% — Clinical-stage biopharma in biologics for autoimmune diseases · Massachusetts
35 ODTX Odyssey Therapeutics, Inc.
United States · score 5.0
 1% 0.9 bn — — — — — — Medicines for autoimmune and inflammatory diseases · Massachusetts
36 MLTX MoonLake Immunotherapeutics
Switzerland · score 0.0
 1% 0.8 bn — — -0.2 bn -27.1% — Clinical-stage biotech in inflammatory skin and joint diseases · Switzerland
37 ANNX Annexon, Inc.
United States · score 0.0
 1% 0.8 bn — — -0.2 bn -25.4% — Biopharma in immunotherapies for neuroinflammatory diseases · California
38 OBX Obsidian Therapeutics, Inc.
United States · score 0.0
 1% 0.7 bn 0.0 bn — -0.1 bn -12.4% — Clinical-stage cell therapies, from Cambridge · Massachusetts
39 PRME Prime Medicine, Inc.
United States · score 0.0
 1% 0.7 bn 0.0 bn -41x -0.2 bn -22.6% — Genetic medicine biotech through precision editing · Massachusetts — revenue of $5m
40 SANA Sana Biotechnology, Inc.
United States · score 0.0
 1% 0.7 bn — — -0.1 bn -19.6% — Engineered cells to repair and replace cells in the body · Washington
41 IMMX Immix Biopharma, Inc.
United States · score 0.0
 1% 0.7 bn — — -0.0 bn -5.7% — Clinical-stage biopharma of CAR-T for AL amyloidosis · California
42 AURA Aura Biosciences, Inc.
United States · score 0.0
 1% 0.7 bn — — -0.1 bn -15.8% — Clinical-stage biotech of therapies for solid tumors · Massachusetts
43 AVTX Avalo Therapeutics, Inc.
United States · score 0.0
 1% 0.6 bn 0.0 bn -1701x -0.1 bn -11.0% — Clinical-stage biotech in anti-IL-1β treatments · Pennsylvania
44 SLDB Solid Biosciences Inc.
United States · score 0.0
 1% 0.6 bn — — -0.2 bn -29.6% — Gene therapy for Duchenne muscular dystrophy and other diseases · Massachusetts
45 ATTO Attovia Therapeutics, Inc.
United States · score 4.0
 1% 0.6 bn — — — — — — Antibody biotech for immune diseases · California
46 CADL Candel Therapeutics, Inc.
United States · score 0.0
 1% 0.6 bn — — -0.1 bn -9.1% — Clinical-stage biopharma of viral immunotherapy · Massachusetts
47 CLYM Climb Bio, Inc.
United States · score 0.0
 1% 0.6 bn — — -0.1 bn -9.5% — Clinical-stage biotech in immune-mediated diseases · Massachusetts
48 CTMX CytomX Therapeutics, Inc.
United States · score 0.0
 0% 0.5 bn 0.0 bn -435.2% -0.1 bn -16.2% — Clinical-stage biopharma in oncology therapies · California — revenue of $18m
49 CBIO CRESCENT BIOPHARMA, INC.
United States · score 0.0
 0% 0.5 bn 0.0 bn -808.1% -0.1 bn -16.0% — Clinical-stage biotech in oncology therapies · Massachusetts — revenue of $12m
50 STTK Shattuck Labs, Inc.
United States · score 0.0
 0% 0.5 bn 0.0 bn -53x -0.0 bn -7.7% — Clinical-stage biotech in antibodies for immune diseases · Texas — revenue of $1m
51 NGNE Neurogene Inc.
United States · score 0.0
 0% 0.5 bn 0.0 bn — -0.1 bn -18.1% — Clinical-stage biotech in neurological diseases · New York
52 EDIT Editas Medicine, Inc.
United States · score 0.0
 0% 0.4 bn 0.1 bn -157.3% -0.1 bn -32.4% — Gene editing for genomic medicines · Massachusetts — revenue of $47m
53 SCTX Scribe Therapeutics, Inc.
United States · score 0.0
 0% 0.4 bn 0.0 bn -97.0% -0.0 bn — -10.4% — In vivo gene editing with CRISPR · California — revenue of $33m
54 ALLO Allogene Therapeutics, Inc.
United States · score 0.0
 0% 0.4 bn 0.0 bn -36x -0.1 bn -22.8% — Clinical-stage immuno-oncology of allogeneic T cells · California — revenue of $5m
55 PROK PROKIDNEY CORP.
United States · score 0.0
 0% 0.4 bn 0.0 bn -103x -0.2 bn -37.9% — Autologous cell therapy for advanced chronic kidney disease · North Carolina
56 CAPR CAPRICOR THERAPEUTICS, INC.
United States · score 0.0
 0% 0.4 bn 0.0 bn — -0.1 bn -29.7% — Biotech in cell therapies for Duchenne muscular dystrophy · California
57 DMAC DiaMedica Therapeutics Inc.
United States · score 0.0
 0% 0.4 bn — — -0.0 bn -7.4% — Clinical-stage biopharma in severe ischemic diseases · Minnesota
58 EIKN Eikon Therapeutics, Inc.
United States · score 5.0
 0% 0.4 bn — — — — — — Late-clinical-stage medicines, with super-resolution microscopy · California
59 TECX Tectonic Therapeutic, Inc.
United States · score 0.0
 0% 0.4 bn — — -0.1 bn -17.5% — Clinical-stage biotech of GPCR-modulating proteins · Massachusetts
60 AGMB AgomAb Therapeutics NV
Belgium · score 0.0
 0% 0.4 bn — — -0.1 bn -14.3% — Therapies for intestinal (Crohn's disease) and lung fibrosis, in clinical stage, from Belgium · Belgium
61 ZURA Zura Bio Ltd
United States · score 0.0
 0% 0.4 bn — — -0.1 bn -17.8% — Clinical-stage biotech in autoimmune and inflammatory diseases · California
62 INDP Indaptus Therapeutics, Inc.
United States · score 0.2
 0% 0.4 bn — — -0.0 bn -4.0% — Systemic immunotherapy against cancer and viruses · New York
63 KYTX Kyverna Therapeutics, Inc.
United States · score 0.0
 0% 0.4 bn — — -0.2 bn -44.1% — Cell therapies for autoimmune diseases · California
64 RZLT Rezolute, Inc.
United States · score 0.0
 0% 0.4 bn — — -0.1 bn -18.1% — Late-stage biopharma in hyperinsulinism-induced hypoglycemia · California
65 ABEO ABEONA THERAPEUTICS INC.
United States · score 0.0
 0% 0.3 bn 0.0 bn -246.4% -0.1 bn -32.3% — Commercial biopharma in cell and gene therapies · Ohio — revenue of $26m
66 IRD Opus Genetics, Inc.
United States · score 0.0
 0% 0.3 bn 0.0 bn -11x -0.0 bn -12.8% — Clinical-stage biopharma in ocular gene therapy · North Carolina — revenue of $10m
67 SRZN Surrozen, Inc./DE
United States · score 0.0
 0% 0.3 bn 0.0 bn -29x -0.0 bn -12.5% — Biotech modulating the Wnt pathway for tissue repair · California — revenue of $12m
68 ARTV Artiva Biotherapeutics, Inc.
United States · score 0.0
 0% 0.3 bn 0.0 bn — -0.1 bn -26.7% — Natural killer cell therapies for autoimmune diseases and cancer · California
69 OCGN Ocugen, Inc.
United States · score 0.0
 0% 0.3 bn 0.0 bn -18x -0.1 bn -22.9% — Gene therapies for retinal diseases · Pennsylvania — revenue of $5m
70 BNTC Benitec Biopharma Inc.
United States · score 0.1
 0% 0.3 bn — — -0.0 bn -5.7% — Clinical-stage genetic medicine biotech · California
71 CABA Cabaletta Bio, Inc.
United States · score 0.0
 0% 0.3 bn — — -0.1 bn -61.5% — Late-stage biotech of T cells for autoimmune diseases · Pennsylvania
72 STRO SUTRO BIOPHARMA, INC.
United States · score 0.0
 0% 0.2 bn 0.1 bn -395.2% -0.1 bn -77.8% — Clinical-stage oncology of antibody-drug conjugates · California — revenue of $46m
73 DTIL PRECISION BIOSCIENCES INC
United States · score 0.0
 0% 0.2 bn 0.1 bn -117.0% -0.1 bn -30.4% — Clinical-stage gene editing with the ARCUS platform · North Carolina — revenue of $45m
74 ALEC Alector, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn -560.0% -0.2 bn -72.8% — Clinical-stage biotech in neurodegenerative diseases · California — revenue of $21m
75 PRQR ProQR Therapeutics N.V.
Netherlands · score 0.0
 0% 0.2 bn 0.0 bn -228.9% -0.1 bn -30.4% — RNA editing therapies, from the Netherlands · Netherlands — revenue of $21m
76 LCTX Lineage Cell Therapeutics, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn -246.6% -0.0 bn -10.1% — Clinical-stage cell replacement therapies · California — revenue of $13m
77 FATE FATE THERAPEUTICS INC
United States · score 0.0
 0% 0.2 bn 0.0 bn -19x -0.1 bn -47.4% — Clinical-stage biopharma of off-the-shelf cell immunotherapies · California — revenue of $6m
78 KROS Keros Therapeutics, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn -572.1% -0.1 bn -22.1% — Clinical-stage biopharma in TGF-beta signaling · Massachusetts — revenue of $15m
79 PYXS Pyxis Oncology, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn -640.3% -0.1 bn -32.3% — Clinical-stage oncology in solid tumors · Massachusetts — revenue of $14m
80 IPHA Innate Pharma SA
France · score 0.0
 0% 0.2 bn 0.0 bn -483.8% -0.1 bn -29.4% — NK cell antibody oncology, from France · France — revenue of $11m
81 MDWD MediWound Ltd.
Israel · score 0.0
 0% 0.2 bn 0.0 bn -170.1% -0.0 bn -17.5% — Enzymatic debridement of burns, from Israel · Israel — revenue of $12m
82 ADAG Adagene Inc.
China · score 0.0
 0% 0.2 bn 0.0 bn -267.4% -0.0 bn -12.7% — Antibodies for oncology with a masking platform · China — revenue of $8m
83 RCKT ROCKET PHARMACEUTICALS, INC.
United States · score 0.0
 0% 0.2 bn 0.0 bn — -0.2 bn -69.3% — Late-stage biotech in gene therapies for rare diseases · New York
84 SABS SAB Biotherapeutics, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn — -0.1 bn -23.2% — Clinical-stage biopharma of human antibodies · Florida
85 LYEL Lyell Immunopharma, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn -9203x -0.1 bn -62.1% — T cell engineering to fight cancer · California
86 CAMP Camp4 Therapeutics Corp
United States · score 0.0
 0% 0.2 bn 0.0 bn -25x -0.0 bn -14.6% — Clinical-stage biopharma in RNA-targeted therapies · Massachusetts — revenue of $4m
87 TRDA Entrada Therapeutics, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn -35x -0.1 bn -71.6% — Clinical-stage biopharma reaching intracellular targets · Massachusetts — revenue of $5m
88 WHWK Whitehawk Therapeutics, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn — -0.1 bn -40.4% — Clinical-stage oncology in targeted delivery of treatments · New Jersey
89 UPB Upstream Bio, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn -50x -0.1 bn -89.0% — Clinical-stage biotech in inflammatory respiratory diseases · Massachusetts — revenue of $3m
90 CMPX Compass Therapeutics, Inc.
United States · score 0.0
 0% 0.2 bn 0.0 bn — -0.1 bn -37.5% — Clinical-stage biopharma of cancer antibodies · Massachusetts
91 LXEO Lexeo Therapeutics, Inc.
United States · score 0.0
 0% 0.2 bn — — -0.1 bn -39.2% — Clinical-stage genetic medicine for cardiovascular diseases · New York
92 LRMR Larimar Therapeutics, Inc.
United States · score 0.0
 0% 0.2 bn — — -0.2 bn -70.9% — Clinical-stage biotech in complex rare diseases · Pennsylvania
93 PEPG PepGen Inc.
United States · score 0.0
 0% 0.2 bn — — -0.1 bn -37.1% — Clinical-stage biotech in neuromuscular oligonucleotides · Massachusetts
94 ELDN Eledon Pharmaceuticals, Inc.
United States · score 0.0
 0% 0.2 bn — — -0.1 bn -42.1% — Clinical-stage biotech in transplant rejection and ALS · California
95 ALXO ALX ONCOLOGY HOLDINGS INC
United States · score 0.0
 0% 0.2 bn — — -0.1 bn -45.0% — Clinical-stage biotech in cancer therapies · California
96 RNA Atrium Therapeutics, Inc.
United States · score 0.0
 0% 0.1 bn 0.0 bn -184.1% -0.1 bn — -43.4% — RNA therapeutics delivered to the heart muscle to treat cardiomyopathies · California — revenue of $36m
97 CUE Cue Biopharma, Inc.
United States · score 1.2
 0% 0.1 bn 0.0 bn — -0.1 bn -43.0% — Clinical-stage biopharma in T cell modulation · Massachusetts — revenue of $38m
98 VYGR Voyager Therapeutics, Inc.
United States · score 0.0
 0% 0.1 bn 0.0 bn -312.6% -0.1 bn -96.1% — Therapies that cross the blood-brain barrier · Massachusetts — revenue of $34m
99 COYA Coya Therapeutics, Inc.
United States · score 0.0
 0% 0.1 bn 0.0 bn -270.2% -0.0 bn -16.0% — Clinical-stage biotech in regulatory T cells · Texas — revenue of $8m
100 ATRA Atara Biotherapeutics, Inc.
United States · score 0.0
 0% 0.1 bn 0.0 bn -269.4% -0.0 bn -24.4% — Allogeneic T-cell immunotherapy for cancer and autoimmune diseases · California — revenue of $6m
101 CTOR CITIUS ONCOLOGY, INC.
United States · score 0.0
 0% 0.1 bn 0.0 bn -648.3% -0.0 bn -8.3% — Targeted cancer therapies · New Jersey — revenue of $7m
102 MOLN MOLECULAR PARTNERS AG
Switzerland · score 0.0
 0% 0.1 bn 0.0 bn — -0.1 bn -38.0% — DARPin proteins for oncology and infections, from Switzerland · Switzerland
103 KRRO Korro Bio, Inc.
United States · score 0.0
 0% 0.1 bn 0.0 bn -45x -0.1 bn -52.0% — Biopharma in genetic medicine through RNA editing · Massachusetts — revenue of $2m
104 NKTX Nkarta, Inc.
United States · score 0.0
 0% 0.1 bn 0.0 bn — -0.1 bn -74.9% — Clinical-stage biopharma in off-the-shelf NK cells · California
105 OTLK Outlook Therapeutics, Inc.
United States · score 0.0
 0% 0.1 bn 0.0 bn -43x -0.1 bn -46.8% — Ophthalmic bevacizumab for retinal diseases · New Jersey — revenue of $1m
106 HURA TuHURA Biosciences, Inc./NV
United States · score 0.0
 0% 0.1 bn 0.0 bn — -0.0 bn -26.4% — Phase III immuno-oncology for resistance to immunotherapies · Florida
107 HUMA Humacyte, Inc.
United States · score 0.0
 0% 0.1 bn 0.0 bn -46x -0.1 bn -87.6% — Bioengineered human tissues and implantable organs · North Carolina — revenue of $2m
108 GNLX GENELUX Corp
United States · score 0.0
 0% 0.1 bn 0.0 bn -4450x -0.0 bn -25.9% — Late clinical-stage oncolytic viral immunotherapy · California
109 RLYB Rallybio Corp
United States · score 6.3
 0% 0.1 bn 0.0 bn 71x 0.0 bn 30.8% — Clinical-stage biotech in severe rare diseases · Connecticut
110 TNYA Tenaya Therapeutics, Inc.
United States · score 0.0
 0% 0.1 bn 0.0 bn -77x -0.1 bn -62.0% — Clinical-stage biotech of therapies for heart disease · California — revenue of $1m
111 CNTB Connect Biopharma Holdings Ltd
United States · score 0.0
 0% 0.1 bn 0.0 bn -23x -0.1 bn -106.9% — Clinical-stage biopharma in asthma and COPD · California — revenue of $3m
112 NBP NovaBridge Biosciences
United States · score 0.0
 0% 0.1 bn — — -0.0 bn -14.4% — Oncology drugs in development · Maryland
113 TARA Protara Therapeutics, Inc.
United States · score 0.0
 0% 0.1 bn — — -0.1 bn -48.3% — Clinical-stage biopharma in cancer and rare diseases · New York
114 ABOS Acumen Pharmaceuticals, Inc.
United States · score 0.0
 0% 0.1 bn — — -0.1 bn -71.7% — Clinical-stage biopharma in Alzheimer's · Massachusetts
115 TLSA Tiziana Life Sciences Ltd
United Kingdom · score 0.0
 0% 0.1 bn — — -0.0 bn -10.6% — Nasal anti-CD3 antibody for multiple sclerosis and neurodegenerative diseases, in clinical stage · United Kingdom
116 ARMP Armata Pharmaceuticals, Inc.
United States · score 0.0
 0% 0.1 bn — — -0.0 bn -22.6% — Late-stage biotech of bacteriophages against resistant bacteria · California
117 ENGN enGene Therapeutics Inc.
Canada · score 0.0
 0% 0.1 bn — — -0.1 bn -98.2% — Gene therapy delivered through mucosal tissues · Canada
118 CNXU Conexeu Sciences Inc.
United States · score 5.0
 0% 0.1 bn — — — — — — Regenerative cell therapies for skin restoration in wound care and aesthetics · Nevada
119 ANIX Anixa Biosciences Inc
United States · score 0.0
 0% 0.1 bn — — -0.0 bn -8.1% — Biotech in cancer therapies and vaccines · California
120 CRBP Corbus Pharmaceuticals Holdings, Inc.
United States · score 0.0
 0% 0.1 bn — — -0.1 bn -100.4% — Clinical-stage pharma in oncology and obesity · Massachusetts
121 EQ Equillium, Inc.
United States · score 0.0
 0% 0.1 bn — — -0.0 bn -25.6% — Biotech in therapies for autoimmune and inflammatory diseases · California
122 PMN ProMIS Neurosciences Inc.
Canada · score 0.0
 0% 0.1 bn — — -0.0 bn -57.1% — Antibodies and vaccines for protein misfolding diseases · Canada
123 ONCY ONCOLYTICS BIOTECH INC
United States · score 0.8
 0% 0.1 bn — — -0.0 bn -41.9% — Clinical-stage biopharma of an oncolytic virus for RAS tumors · California
124 XBIT XBiotech Inc.
United States · score 0.0
 0% 0.1 bn — — -0.0 bn -66.9% — Biopharma developing human monoclonal antibodies · Texas
125 OSTX OS Therapies Inc
United States · score 0.5
 0% 0.1 bn — — -0.0 bn -32.4% — HER2-targeted immunotherapy against metastasis · Maryland
126 HOWL Werewolf Therapeutics, Inc.
United States · score 0.0
 0% 0.1 bn — — -0.0 bn -59.7% — Biopharma in therapies that stimulate the immune system · Massachusetts
127 BSEM BioStem Technologies, Inc.
United States · score 0.1
 0% 0.0 bn 0.0 bn -81.8% -0.0 bn -32.1% — Placental tissue products for wound healing · Florida — revenue of $35m
128 CELU Celularity Inc
United States · score 0.0
 0% 0.0 bn 0.0 bn -374.7% -0.0 bn -23.9% — Cell and regenerative medicine derived from human placenta · New Jersey — revenue of $19m
129 MGX Metagenomi Therapeutics, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -418.5% -0.1 bn -279.5% — In vivo genome editing for genetic medicine · California — revenue of $22m
130 CRBU Caribou Biosciences, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -10x -0.1 bn -192.7% — Clinical-stage biopharma of CRISPR genome editing · California — revenue of $10m
131 IMMP IMMUTEP Ltd
Australia · score 0.0
 0% 0.0 bn 0.0 bn -594.7% -0.0 bn -187.8% — LAG-3 immunotherapies for cancer, from Australia · Australia — revenue of $7m
132 KYNB KYNTRA BIO, INC.
United States · score 0.0
 0% 0.0 bn 0.0 bn 28x -0.0 bn -177.9% — CD46-targeted antibody-drug conjugate for advanced prostate cancer · California — revenue of $6m
133 TCRX TScan Therapeutics, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -17x -0.1 bn -834.1% — Engineered T cell receptor therapies for cancer · Massachusetts — revenue of $7m
134 IMRN Immuron Ltd
Australia · score 0.0
 0% 0.0 bn 0.0 bn -47.7% 0.0 bn -29.6% — Oral antibodies from bovine colostrum against travelers' diarrhea (Travelan) and gut infections · Australia — revenue of $5m
135 IBIO iBio, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -330x -0.0 bn -48.7% — Clinical-stage biotech in AI-designed antibodies · New York
136 MREO Mereo BioPharma Group plc
United Kingdom · score 0.0
 0% 0.0 bn 0.0 bn — -0.0 bn -52.6% — Therapies for rare diseases, from the United Kingdom · United Kingdom
137 IMA ImageneBio, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -66x -0.1 bn -115.8% — Therapies for immune and inflammatory diseases · California
138 INMB Inmune Bio, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -368x -0.0 bn -37.5% — Reprogramming the innate immune system for cancer and Alzheimer's · Florida
139 ALGS Aligos Therapeutics, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -20x -0.1 bn -311.8% — Clinical-stage biotech for liver and viral diseases · California — revenue of $4m
140 MCRB Seres Therapeutics, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -12x -0.1 bn -212.8% — Clinical-stage biotech of live biotherapeutics · Massachusetts — revenue of $2m
141 KRSA Korsana Biosciences, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -353.0% 0.0 bn -21.2% — Anti-amyloid therapy with brain shuttle delivery for Alzheimer's and other neurodegenerative diseases · Massachusetts — revenue of $2m
142 MRKR Marker Therapeutics, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -220.5% -0.0 bn -48.8% — Clinical-stage immuno-oncology in T cell therapies · Texas — revenue of $4m
143 GUTS FRACTYL HEALTH, INC.
United States · score 0.0
 0% 0.0 bn 0.0 bn — -0.1 bn -453.5% — Metabolic therapies for obesity and type 2 diabetes · Massachusetts
144 ATYR aTYR PHARMA INC
United States · score 0.0
 0% 0.0 bn 0.0 bn -320x -0.1 bn -324.4% — Clinical-stage biotech for fibrosis and inflammation · California
145 BCDA BioCardia, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn — -0.0 bn -55.7% — Autologous cell therapy for heart failure and angina, with its own delivery catheter · California
146 GDTC CytoMed Therapeutics Ltd
Singapore · score 0.0
 0% 0.0 bn 0.0 bn -12x 0.0 bn -33.4% — Clinical-stage cell immunotherapies, from Singapore · Singapore
147 BFRG BullFrog AI Holdings, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -20x -0.0 bn -56.1% — AI applied to drug development · Maryland
148 BOLT Bolt Biotherapeutics, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -611.5% -0.0 bn -404.3% — Immunotherapy with antibody-agonist conjugates · California — revenue of $5m
149 SNTI Senti Biosciences Holdings, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -901x -0.0 bn -535.9% — Clinical-stage biotech in cell and gene therapies · California
150 AIM AIM ImmunoTech Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -150x -0.0 bn -224.6% — Ampligen immunotherapy for cancer and viral diseases · Florida
151 XBIO Xenetic Biosciences, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -75.9% 0.0 bn -51.4% — Biopharma in immuno-oncology technologies · Massachusetts — revenue of $3m
152 LGVN Longeveron Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -20x -0.0 bn -466.7% — Clinical-stage cell therapies · Florida — revenue of $1m
153 AZTR Azitra, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn — -0.0 bn -253.9% — Precision dermatology biopharma with proteins and live biologics · Connecticut
154 PMCB PharmaCyte Biotech, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn — 0.0 bn -106.5% — Live-cell encapsulation for cancer therapy · Nevada
155 LNAI Lunai Bioworks Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -69x -0.0 bn -220.4% — AI-driven preclinical biotech · California
156 BRTX BioRestorative Therapies, Inc.
United States · score 0.0
 0% 0.0 bn 0.0 bn -31x -0.0 bn -596.7% — Adult stem cell therapies for disc and spine · New York
157 INKT MiNK Therapeutics, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -14.0% — Allogeneic invariant natural killer T cell therapies · New York
158 KLRS Kalaris Therapeutics, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -90.6% — Clinical-stage biopharma for retinal diseases · New Jersey
159 TVGN Tevogen Inc.
United States · score 0.7
 0% 0.0 bn — — -0.0 bn -26.4% — Clinical-stage immunotherapy of cytotoxic T lymphocytes · New Jersey
160 ACET Adicet Bio, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.1 bn -200.4% — Clinical-stage biotech in allogeneic gamma-delta T cells · Massachusetts
161 TIL Instil Bio, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -60.1% — Biotech pursuing therapeutic opportunities · Texas
162 GNTA Genenta Science S.p.A.
Italy · score 0.0
 0% 0.0 bn — — -0.0 bn -24.2% — Cell therapies for solid tumors, from Italy · Italy
163 BCTX BriaCell Therapeutics Corp.
Canada · score 0.0
 0% 0.0 bn — — -0.0 bn -104.8% — Off-the-shelf personalized immunotherapy for cancer · Canada
164 CVM CEL SCI CORP
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -57.8% — Late-stage biotech in cancer immunotherapy · Virginia
165 RNAZ Transcode Therapeutics, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -78.5% — Clinical-stage immuno-oncology and RNA therapies · Massachusetts
166 NXTC NextCure, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -142.2% — Licensed antibody-drug conjugates in clinical stage · Maryland
167 CNTX Context Therapeutics Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -155.4% — Clinical-stage biopharma in bispecific antibodies · Pennsylvania
168 ESLA Estrella Immunopharma, Inc.
United States · score 0.4
 0% 0.0 bn — — -0.0 bn -56.9% — Clinical-stage biopharma of T-cell therapies · California
169 JSPR Jasper Therapeutics, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.1 bn -379.5% — Clinical-stage biotech in mast cell-driven diseases · California
170 PASG Passage BIO, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -291.3% — Clinical-stage genetic medicine for neurodegenerative diseases · Pennsylvania
171 INAB IN8BIO, INC.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -134.2% — Clinical-stage biopharma in gamma-delta T cells · New York
172 PHIO Phio Pharmaceuticals Corp.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -120.9% — Clinical-stage biopharma in gene silencing for immuno-oncology · Pennsylvania
173 LTRN Lantern Pharma Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -146.7% — AI-driven oncology drug discovery · Texas
174 TOVX Theriva Biologics, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -138.7% — Clinical-stage biotech in oncology therapies · Maryland
175 CMMB Chemomab Therapeutics Ltd.
Israel · score 0.0
 0% 0.0 bn — — -0.0 bn -104.0% — Clinical-stage biotech in fibrotic and inflammatory diseases · Israel
176 SKYE Skye Bioscience, Inc.
United States · score 0.1
 0% 0.0 bn — — -0.0 bn -570.7% — Clinical-stage biotech in obesity and metabolic disorders · California
177 FBLG FibroBiologics, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -234.9% — Fibroblast therapies for chronic diseases · Texas
178 IMNN Imunon, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -271.1% — Clinical-stage immunotherapy and gene therapy · New Jersey
179 LIMN Liminatus Pharma, Inc.
United States · score 1.6
 0% 0.0 bn — — 0.0 bn -94.9% — Single-asset preclinical biopharma · California
180 PPCB Propanc Biopharma, Inc.
Australia · score 0.0
 0% 0.0 bn — — -0.0 bn -177.8% — Pancreatic proenzymes against tumor recurrence and metastasis · Australia
181 ERNA Ernexa Therapeutics Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -277.3% — Allogeneic cell therapies derived from iPSCs · Massachusetts
182 APVO Aptevo Therapeutics Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -873.9% — Clinical-stage biotech in cancer immunotherapy · Washington
183 MBIO MUSTANG BIO, INC.
United States · score 0.0
 0% 0.0 bn — — 0.0 bn -161.1% — Licensing and development of therapeutic technologies · Massachusetts
184 KAPA Kairos Pharma, LTD.
United States · score 0.0
 0% 0.0 bn — — 0.0 bn -208.9% — Clinical-stage biopharma in immune suppression and resistance · California
185 GNPX Genprex, Inc.
United States · score 0.0
 0% 0.0 bn — — -0.0 bn -915.5% — Clinical-stage gene therapy for large populations · Texas
186 HCWB HCW Biologics Inc.
United States · score 0.4
 — — 0.0 bn -83.1% -0.0 bn — — Clinical-stage biopharma in fusion immunotherapies · Florida — revenue of $7m
187 EVGN Evogene Ltd.
Israel · score 0.4
 — — 0.0 bn -471.9% -0.0 bn — — Computational discovery of molecules for pharma and agriculture, from Israel · Israel — revenue of $2m
188 SCNI Scinai Immunotherapeutics Ltd.
Israel · score 0.8
 — — 0.0 bn -174.8% -0.0 bn — — Immunotherapies and biologics, from Israel · Israel — revenue of $1m
189 YARW Yarrow Bioscience, Inc.
United States · score 0.8
 — — 0.0 bn -39x -0.0 bn — — Anti-TSHR antibody for Graves' disease and thyroid eye disease · Connecticut
190 CLGN CollPlant Biotechnologies Ltd
Israel · score 0.5
 — — 0.0 bn -39x -0.0 bn — — Recombinant collagen for regenerative and aesthetic medicine, from Israel · Israel
191 CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
United States · score 0.6
 — — 0.0 bn -2014x -0.0 bn — — Commercial-stage biotech in regenerative therapies · Arizona
192 ENLV Enlivex Ltd.
Israel · score 3.5
 — — — — -0.0 bn — — Cell therapy for severe inflammatory diseases, from Israel · Israel
193 AKTX Akari Therapeutics Plc
United States · score 1.1
 — — — — -0.0 bn — — Antibody-drug conjugates for oncology · Florida
194 EDSA Edesa Biotech, Inc.
Canada · score 0.9
 — — — — -0.0 bn — — Biopharma in inflammatory and immune-mediated diseases · Canada
195 NCEL NewcelX Ltd.
Switzerland · score 3.0
 — — — — -0.0 bn — — Stem cell-derived cell therapies for type 1 diabetes and neurodegenerative diseases · Switzerland
196 PDSB PDS Biotechnology Corp
United States · score 1.8
 — — — — -0.0 bn — — Clinical-stage immunotherapy for cancer and infectious diseases · New Jersey
197 GTBP GT Biopharma, Inc.
United States · score 0.9
 — — — — -0.0 bn — — Clinical-stage immuno-oncology biopharma with TriKE · California
198 CLDI Calidi Biotherapeutics, Inc.
United States · score 0.8
 — — — — -0.0 bn — — Biotech in targeted genetic medicine · California
199 SLXN Silexion Therapeutics Corp
Israel · score 2.8
 — — — — -0.0 bn — — Clinical-stage biotech in KRAS-mutated cancers · Israel
200 SLBT SL Science Holding Ltd
Taiwan · score 4.0
 — — — — — — — — Cell and gene therapies · Taiwan

Other industries in the same sector

and 22 industries more
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.

The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.

Have a question or a suggestion, or found a mistake?

Write here: a question about the score, a missing company or industry, a number that looks wrong. Every message is read, and the email is so I can reply.